Key Takeaways ABBV is counting on Skyrizi and Rinvoq to drive growth post-Humira as Q2 results near. Skyrizi and Rinvoq saw broad uptake across IBD and new indications like GCA and atopic dermatitis. ABBV expects combined Q2 sales of $6 billion from Skyrizi and Rinvoq to support 2025 growth.AbbVie (ABBV) has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know the sales numbe ...

In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.25%). Since then, both have produced strong returns and have been great picks for income-seeking investors, thanks to consistent payout hikes. That likely won't change soon.These healthcare leaders should continue to perform well and reward shareholders with dividend increases for a long time. Read on to find out more. 1. AbbVieAbbVie is a pharmaceutical leader with a ...

该方法类似于mRNA疫苗，仅需简单注射，就能在体内生成CAR-T细胞疗法，无需实验室细胞制造和体 外扩增，有望解决当前CAR-T细胞疗法工艺复杂、周期长、价格高昂等关键难题。 当地时间6月30日，制药公司艾伯维宣布，将以21亿美元的价格收购体内CAR-T细胞疗法开发商Capstan Therapeutics，以扩大自身免疫性疾病疗法的产品线。 自2023年艾伯维的明星药物阿达木单抗（修美乐）专利到期以来，艾伯维已斥资超过200亿美元进行大 手笔收购。该公司正在与Vertex、百时美施贵宝（BMS）等制药巨头在自身免疫药物领域展开竞争。 艾伯维最新押注的Capstan基于mRNA技术开发CAR-T疗法。通过此项交易，艾伯维将获得Capstan公司 包括脂质纳米颗粒（tLNP）在内的核心平台技术。该技术可通过重新编程细胞治疗疾病，在自身免疫 性疾病领域具有广阔的潜力。 有市场研究数据显示，CAR-T疗法市场规模今年将突破110亿美元，到2034年有望飙升至接近2000亿美 元的规模。 Capstan公司成立于2022年，由美国宾夕法尼亚大学医学院顶尖团队领衔。该公司科学团队创始人阵容 豪华，包括CAR-T先驱卡尔 ...

Core Viewpoint - The healthcare sector is positioned as a strong long-term investment opportunity, with a focus on companies that have shown adaptability and are well-prepared for future challenges [2]. Group 1: Abbott Laboratories - Abbott Laboratories, founded in 1888, has a market capitalization of $240 billion and offers diverse healthcare products across multiple sectors [4]. - The company is a leader in medical devices, diagnostics, nutritional products, and established pharmaceuticals, with notable products like the MitraClip and FreeStyle Libre [5][6]. - Abbott anticipates an 8% year-over-year revenue growth in 2025 and continues to innovate, recently receiving the European CE Mark for the Volt PFA System [7][8]. - Abbott has a strong dividend history, having increased its dividend for 53 consecutive years [8]. Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has a market capitalization of approximately $328 billion and generated $56.3 billion in sales last year [9][10]. - The company has successfully navigated the loss of U.S. exclusivity for its top product, Humira, by investing in R&D and acquisitions, leading to a robust product pipeline [11]. - AbbVie’s successors to Humira, Rinvoq and Skyrizi, are projected to generate combined sales of $31 billion by 2027, surpassing Humira's peak sales [12]. - AbbVie has increased its dividend by a cumulative 310% since its spin-off, with a forward dividend yield of 3.51% [12]. - The stock is considered relatively inexpensive, trading at 15.2 times forward earnings, with growth potential from new products [13].

Key Takeaways ABBV stock rose 8% in six months, gaining over $24B in market cap as investors respond to post-Humira growth. Skyrizi and Rinvoq brought in $5.1B in Q1 2025 sales, up 65%, with $31B projected by 2027. ABBV pipeline gains from 20 recent deals and a push into oncology, neuroscience and obesity therapies.AbbVie (ABBV) stock has risen 8.0% in six months, adding more than $24 billion to its market value.AbbVie has successfully navigated the loss of exclusivity (“LOE”) of its blockbuster drug, Hum ...

Key Takeaways LLY's Mounjaro and Zepbound now generate 50% of revenues and drive strong growth despite recent headwinds. ABBV expects $24.7B in 2025 sales from Skyrizi and Rinvoq, helping offset Humira's post-LOE revenue decline. LLY expects 32% sales growth in 2025, but ABBV boasts rising estimates and a lower valuation.Eli Lilly (LLY) and AbbVie (ABBV) are U.S.-based pharmaceutical powerhouses with blockbuster drug portfolios, robust pipelines, strong market capitalization and global footprint. Both com ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores. ...

Industry Overview - The Zacks Large Cap Pharmaceuticals industry includes major global companies developing multi-million-dollar drugs across various therapeutic areas such as neuroscience, cardiovascular, metabolism, rare diseases, immunology, and oncology [4] - Continuous innovation and significant investment in R&D are defining characteristics of these companies, with regular mergers and acquisitions being common [4][5] Current Market Conditions - The industry has shown resilience amid broader macroeconomic uncertainties, with a year-to-date performance increase of 3.9%, outperforming the Zacks Medical Sector's decline of 1.5% and the S&P 500's rise of 1.7% [14] - The current forward 12-month price-to-earnings (P/E) ratio for the industry is 15.65X, lower than the S&P 500's 21.89X and the Zacks Medical Sector's 19.31X, indicating potential value [17] Key Players and Performance - **Bayer**: Key drugs like Nubeqa and Kerendia are driving growth, with plans for new drug launches in 2025. The stock has risen 61.9% year-to-date, with 2025 EPS estimates increasing from $1.19 to $1.25 [20][22] - **Pfizer**: Strengthened its oncology position with the acquisition of Seagen. Despite challenges from declining COVID-19 product sales and patent expirations, non-COVID operational revenues are improving. The stock has lost 4.2% year-to-date, but 2025 EPS estimates have risen from $2.98 to $3.06 [25][26][28] - **Novartis**: Following the separation of Sandoz, it has a strong portfolio with drugs like Kisqali and Leqvio. The stock has risen 25.6% year-to-date, with 2025 EPS estimates increasing from $8.46 to $8.74 [31][32] - **AbbVie**: Successfully transitioned from the loss of exclusivity of Humira with new drugs like Skyrizi and Rinvoq. The stock has risen 9.5% year-to-date, with stable 2025 EPS estimates at $12.28 [35][37] - **Sanofi**: Dupixent is a key growth driver, supported by a strong vaccine portfolio. The stock has risen 6.3% year-to-date, with 2025 EPS estimates increasing from $4.43 to $4.56 [40][42] M&A and Innovation Trends - The industry is characterized by aggressive M&A activity, with large pharmaceutical companies acquiring innovative small and mid-cap biotech firms to enhance their pipelines [6][7] - Recent notable M&A activity includes Sanofi's offer to acquire Blueprint Medicines for approximately $9.5 billion, indicating continued robust M&A activity expected throughout the year [8]

Core Insights - The article reflects on a past investment in Galapagos and the impact of FDA decisions on stock performance, highlighting the risks associated with pharmaceutical investments [1] - The author emphasizes the importance of specific investment criteria, including revenue growth, earnings growth, free cash flow, and favorable valuations [1] Investment Criteria - Companies should demonstrate growth in revenue, earnings, and free cash flow [1] - Excellent growth prospects are essential for potential investments [1] - Favorable valuations are a key consideration for stock selection [1] - Preference is given to companies with high free cash flow margins, dividend stocks, and those with generous share repurchase programs [1]

Core Insights - AbbVie's RINVOQ (upadacitinib) has received FDA approval for the treatment of giant cell arteritis, marking it as the first oral JAK inhibitor approved for this condition in Western countries, and the ninth indication for the drug [1][6] Group 1: Market Dynamics - The approval of RINVOQ has intensified competition among pharmaceutical companies in the giant cell arteritis market [1] - DelveInsight estimates the giant cell arteritis market size to grow from USD 960 million in 2023 at a significant CAGR by 2034, driven by factors such as an increasing geriatric population and rising prevalence of cardiovascular disorders [14] Group 2: Treatment Landscape - The primary treatment for giant cell arteritis has traditionally involved high doses of corticosteroids like prednisone, with the aim of preventing serious complications such as blindness [3] - ACTEMRA/ROACTEMRA (tocilizumab) was the first approved treatment for giant cell arteritis in Europe, with its approval supported by the Phase III GiACTA study demonstrating improved remission rates [4][7] - RINVOQ's pivotal Phase 3 SELECT-GCA trial showed that 46.4% of patients achieved sustained remission with RINVOQ compared to 29.0% on placebo [7] Group 3: Emerging Therapies - Companies like Novartis and CSL/Kiniksa Pharmaceuticals are conducting clinical trials for new treatment options, indicating a need for more effective therapies in the giant cell arteritis space [10][12] - The anticipated launch of emerging therapies is expected to transform the market landscape, offering new standards of care and opportunities for innovation [13]